>> Companies like STPT popping up all over because single mutation disease easier to crack.
If it were so easy to crack, why would no drug get approved for DMD in such a long time? If it were so much easier, why would someone like GSK fail miserably in this space? I guess if it isn't as easy to copy as some thought. By the way, I was talking about trial design easier vs difficult, but somehow someone has to whine about rare disease companies in general at every opportunity. Sure, it wasn't criticism.
>> Defensive about it
Why would I get defensive about this type of nonsense? I am just surprised some people would rather whine constantly about rare disease companies than actually learn something they don't know. I guess some just can't get themselves out of their own narrow minds. I wouldn't waste my time to reply in the future. You can take my word!
